Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
Zhu Y, Zerdes I, Matikas A, Cruz IR, Bergqvist M, Elinder E, Bosch A, Lindman H, Einbeigi Z, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Hellstrom M, Johansson H, Wang K, Bergh JCS, Hatschek T, Foukakis T. Zhu Y, et al. Among authors: bosch a. Breast Cancer Res Treat. 2024 Apr;204(2):299-308. doi: 10.1007/s10549-023-07200-x. Epub 2024 Jan 4. Breast Cancer Res Treat. 2024. PMID: 38175448 Free PMC article. Clinical Trial.
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.
Matikas A, Johansson H, Grybäck P, Bjöhle J, Acs B, Boyaci C, Lekberg T, Fredholm H, Elinder E, Margolin S, Isaksson-Friman E, Bosch A, Lindman H, Adra J, Andersson A, Agartz S, Hellström M, Zerdes I, Hartman J, Bergh J, Hatschek T, Foukakis T. Matikas A, et al. Among authors: bosch a. Clin Cancer Res. 2023 Feb 1;29(3):532-540. doi: 10.1158/1078-0432.CCR-22-2829. Clin Cancer Res. 2023. PMID: 36449695 Clinical Trial.
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort.
Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Ullén S, Leandersson K, Bosch A, Staaf J, Killander F, Niméus E. Sigurjonsdottir G, et al. Among authors: bosch a. Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07561-x. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39656429
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Bosch A, Staaf J, Killander F, Niméus E. Sigurjonsdottir G, et al. Among authors: bosch a. Breast Cancer Res. 2023 Oct 10;25(1):123. doi: 10.1186/s13058-023-01724-2. Breast Cancer Res. 2023. PMID: 37817263 Free PMC article.
High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
Godina C, Khazaei S, Belting M, Vallon-Christersson J, Nodin B, Jirström K, Isaksson K, Bosch A, Jernström H. Godina C, et al. Among authors: bosch a. PLoS One. 2024 Jul 3;19(7):e0305222. doi: 10.1371/journal.pone.0305222. eCollection 2024. PLoS One. 2024. PMID: 38959243 Free PMC article.
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus.
Kaidar-Person O, Pfob A, Gentilini OD, Borisch B, Bosch A, Cardoso MJ, Curigliano G, De Boniface J, Denkert C, Hauser N, Heil J, Knauer M, Kühn T, Lee HB, Loibl S, Mannhart M, Meattini I, Montagna G, Pinker K, Poulakaki F, Rubio IT, Sager P, Steyerova P, Tausch C, Tramm T, Vrancken Peeters MJ, Wyld L, Yu JH, Weber WP, Poortmans P, Dubsky P. Kaidar-Person O, et al. Among authors: bosch a. EClinicalMedicine. 2023 Jul 14;61:102085. doi: 10.1016/j.eclinm.2023.102085. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37528842 Free PMC article. Review.
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
Loibl S, Azim HA Jr, Bachelot T, Berveiller P, Bosch A, Cardonick E, Denkert C, Halaska MJ, Hoeltzenbein M, Johansson ALV, Maggen C, Markert UR, Peccatori F, Poortmans P, Saloustros E, Saura C, Schmid P, Stamatakis E, van den Heuvel-Eibrink M, van Gerwen M, Vandecaveye V, Pentheroudakis G, Curigliano G, Amant F. Loibl S, et al. Among authors: bosch a. Ann Oncol. 2023 Oct;34(10):849-866. doi: 10.1016/j.annonc.2023.08.001. Epub 2023 Aug 10. Ann Oncol. 2023. PMID: 37572987 Free article.
1,153 results